MDGL Relative Valuation
MDGL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MDGL is overvalued; if below, it's undervalued.
Historical Valuation
Madrigal Pharmaceuticals Inc (MDGL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.01. The fair price of Madrigal Pharmaceuticals Inc (MDGL) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：579.89
Fair
354.36
PE
1Y
3Y
5Y
Trailing
Forward
-379.52
EV/EBITDA
Madrigal Pharmaceuticals Inc. (MDGL) has a current EV/EBITDA of -379.52. The 5-year average EV/EBITDA is -21.08. The thresholds are as follows: Strongly Undervalued below -138.58, Undervalued between -138.58 and -79.83, Fairly Valued between 37.67 and -79.83, Overvalued between 37.67 and 96.42, and Strongly Overvalued above 96.42. The current Forward EV/EBITDA of -379.52 falls within the Strongly Undervalued range.
274.19
EV/EBIT
Madrigal Pharmaceuticals Inc. (MDGL) has a current EV/EBIT of 274.19. The 5-year average EV/EBIT is -3.73. The thresholds are as follows: Strongly Undervalued below -95.32, Undervalued between -95.32 and -49.52, Fairly Valued between 42.07 and -49.52, Overvalued between 42.07 and 87.86, and Strongly Overvalued above 87.86. The current Forward EV/EBIT of 274.19 falls within the Strongly Overvalued range.
9.56
PS
Madrigal Pharmaceuticals Inc. (MDGL) has a current PS of 9.56. The 5-year average PS is 47.73. The thresholds are as follows: Strongly Undervalued below -151.22, Undervalued between -151.22 and -51.75, Fairly Valued between 147.20 and -51.75, Overvalued between 147.20 and 246.67, and Strongly Overvalued above 246.67. The current Forward PS of 9.56 falls within the Historic Trend Line -Fairly Valued range.
34.96
P/OCF
Madrigal Pharmaceuticals Inc. (MDGL) has a current P/OCF of 34.96. The 5-year average P/OCF is -8.51. The thresholds are as follows: Strongly Undervalued below -88.69, Undervalued between -88.69 and -48.60, Fairly Valued between 31.59 and -48.60, Overvalued between 31.59 and 71.68, and Strongly Overvalued above 71.68. The current Forward P/OCF of 34.96 falls within the Overvalued range.
58.60
P/FCF
Madrigal Pharmaceuticals Inc. (MDGL) has a current P/FCF of 58.60. The 5-year average P/FCF is -29.88. The thresholds are as follows: Strongly Undervalued below -271.02, Undervalued between -271.02 and -150.45, Fairly Valued between 90.69 and -150.45, Overvalued between 90.69 and 211.26, and Strongly Overvalued above 211.26. The current Forward P/FCF of 58.60 falls within the Historic Trend Line -Fairly Valued range.
Madrigal Pharmaceuticals Inc (MDGL) has a current Price-to-Book (P/B) ratio of 21.04. Compared to its 3-year average P/B ratio of 32.83 , the current P/B ratio is approximately -35.90% higher. Relative to its 5-year average P/B ratio of 26.60, the current P/B ratio is about -20.91% higher. Madrigal Pharmaceuticals Inc (MDGL) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -6.53%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -9.22% , the current FCF yield is about -100.00% lower.
21.27
P/B
Median3y
32.83
Median5y
26.60
-1.23
FCF Yield
Median3y
-6.53
Median5y
-9.22
Competitors Valuation Multiple
The average P/S ratio for MDGL's competitors is , providing a benchmark for relative valuation. Madrigal Pharmaceuticals Inc Corp (MDGL) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 362.03%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of MDGL increased by 89.98% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 62.18M to 287.27M.
The secondary factor is the Margin Expansion, contributed -76.89%to the performance.
Overall, the performance of MDGL in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Madrigal Pharmaceuticals Inc (MDGL) currently overvalued or undervalued?
What is Madrigal Pharmaceuticals Inc (MDGL) fair value?
How does MDGL's valuation metrics compare to the industry average?
What is the current P/B ratio for Madrigal Pharmaceuticals Inc (MDGL) as of Dec 05 2025?
What is the current FCF Yield for Madrigal Pharmaceuticals Inc (MDGL) as of Dec 05 2025?
What is the current Forward P/E ratio for Madrigal Pharmaceuticals Inc (MDGL) as of Dec 05 2025?